Advertisement
Advertisement

EDSA

EDSA logo

Edesa Biotech, Inc. Common Shares

5.43
USD
Sponsored
+0.17
+3.13%
Aug 10, 11:56 UTC -4
Open

EDSA Earnings Reports

Positive Surprise Ratio

EDSA beat 20 of 31 last estimates.

65%

Next Report

Date of Next Report
Dec 10, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.66
Implied change from Q3 26 (Revenue/ EPS)
--
/
--
Implied change from Q4 25 (Revenue/ EPS)
--
/
+106.25%

Edesa Biotech, Inc. Common Shares earnings per share and revenue

On Aug 06, 2026, EDSA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.59 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q4 26, 4 analysts forecast an EPS of -0.66 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
logo
Lexicon Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.06
Surprise
-17.19%
logo
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
logo
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
logo
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
logo
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
logo
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
logo
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
logo
MBX Biosciences, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.78
Surprise
-22.16%
logo
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
FAQ
For Q3 2026, Edesa Biotech, Inc. Common Shares reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for Dec 10, 2026.
Based on 4 analysts, Edesa Biotech, Inc. Common Shares is expected to report EPS of -$0.66 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement